CD47 Inhibitor Drug Clinical Trials Market Outlook to 2028 - Emerging CD47 Inhibitor Clinical Trials Showcase Potential Cancer Treatment Breakthroughs
06 sept. 2024 06h48 HE
|
Research and Markets
Dublin, Sept. 06, 2024 (GLOBE NEWSWIRE) -- The "Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028" report has been added to ResearchAndMarkets.com's offering....
Pharmacovigilance Market - Global Forecasts from 2024 to 2029: Increased Prevalence of ADRs to Drive Expansion
16 août 2024 07h13 HE
|
Research and Markets
Dublin, Aug. 16, 2024 (GLOBE NEWSWIRE) -- The "Global Pharmacovigilance Market - Forecasts from 2024 to 2029" report has been added to ResearchAndMarkets.com's offering.The global pharmacovigilance...
Global VISTA Inhibitor Clinical Trials & Market Opportunity Insight 2024: Widening Research Purview - From Cancer to Autoimmune Disorders
04 juil. 2024 04h03 HE
|
Research and Markets
Dublin, July 04, 2024 (GLOBE NEWSWIRE) -- The "Global VISTA Inhibitor Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering. The...
Global LAG-3 Inhibitors Market, Drug Sales & Clinical Trials Market Report: Featuring Abeome, ABL Bio, Agenus, Akeso Biopharma, AnaptysBio, EpimAb Biotherapeutics, Immutep, Incyte and Y-Biologics
20 juin 2024 04h23 HE
|
Research and Markets
Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "Global LAG-3 Inhibitors Market, Drug Sales & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering. In recent...
Project Management in Drug Development Webinar
13 juin 2024 09h30 HE
|
Research and Markets
Dublin, June 13, 2024 (GLOBE NEWSWIRE) -- The "Project Management in Drug Development" training has been added to ResearchAndMarkets.com's offering. Project management is crucial to drug...
GPRC5D Targeting Drugs Market Opportunity and Clinical Trials Insight 2024: Insight on 15+ Drugs in Clinical Trials
07 juin 2024 03h32 HE
|
Research and Markets
Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Global GPRC5D Targeting Drugs Market Opportunity and Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. In...
FDA Grants Orphan Drug Designation to Biompharma’s Bi104, a microbiome-modifying biologic, for the treatment of Angelman Syndrome
08 mai 2024 09h25 HE
|
Biom Pharmaceutical Corporation
Sarasota, Florida, May 08, 2024 (GLOBE NEWSWIRE) -- BIOM Pharmaceutical Corporation is thrilled to announce that Bi104, its innovative drug product, has been granted orphan-drug designation by the...
Global CD70 Targeting Therapies Market & Clinical Trials Report 2024 - Insight by Company, Country, Indication & Phase
29 avr. 2024 07h32 HE
|
Research and Markets
Dublin, April 29, 2024 (GLOBE NEWSWIRE) -- The "Global CD70 Targeting Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. ...
Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024 - Groundbreaking Advances in PLK Targeted Therapies Promise to Revolutionize Treatment for Cancer and Other Diseases
29 avr. 2024 06h53 HE
|
Research and Markets
Dublin, April 29, 2024 (GLOBE NEWSWIRE) -- The "Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's...
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
16 avr. 2024 08h00 HE
|
PharmaTher Holdings Ltd.
TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, provides an update of its...